10-K/A: TherapeuticsMD Faces Going Concern Amid Legal Battles

TherapeuticsMD, a pharmaceutical royalty company, reported reduced net losses in 2025 but faces substantial doubt about its ability to continue as a going concern due to ongoing legal disputes and liquidity challenges.

Summary

• TherapeuticsMD transitioned to a pharmaceutical royalty company in December 2022, focusing on royalties from licensed products like IMVEXXY, BIJUVA, and ANNOVERA.
• The company reported a net loss from continuing operations of $0.653 million in 2025, a significant improvement from a $2.312 million loss in 2024.
• License revenue increased by 71.6% to $3.022 million in 2025, up from $1.761 million in 2024, primarily due to changes in sales of licensed products.
• Cash and cash equivalents stood at $7.483 million as of December 31, 2025.
• The company is involved in multiple legal disputes with Mayne Pharma regarding net working capital allowances, breach of contract, and fraudulent inducement.
• Ongoing patent infringement lawsuits exist with Teva Pharmaceuticals and Sun Pharma concerning generic versions of IMVEXXY, with patents expiring in 2032 or 2033.
• The independent registered public accounting firm, Carr, Riggs & Ingram, L.L.C., included an explanatory paragraph in their opinion raising substantial doubt about the company's ability to continue as a going concern.
• TherapeuticsMD operates with a very lean structure, employing only one full-time executive (CEO Marlan D. Walker) and engaging external consultants for other functions.
• Stockholders approved an increase in authorized common stock shares from 32 million to 640 million on December 15, 2025, effective January 5, 2026.

Sentiment

Score: 3

Explanation: StockSavvy.ai views this filing with a low sentiment score due to the explicit 'going concern' warning from the auditor, coupled with multiple ongoing legal battles that pose significant financial and operational risks, despite some improvements in royalty revenue.

Positives

• Net loss from continuing operations significantly decreased to $0.653 million in 2025 from $2.312 million in 2024, indicating improved operational efficiency.
• License revenue increased by 71.6% to $3.022 million in 2025, up from $1.761 million in 2024, driven by higher sales of licensed products.
• Net cash provided by operating activities from continuing operations increased to $2.454 million in 2025 from $1.170 million in 2024.
• Sublease income increased to $1.847 million in 2025 from $1.352 million in 2024, partially offsetting other income decreases.

Negatives

• The company continues to incur net losses, with a net loss of $0.569 million in 2025 and $2.181 million in 2024.
• There is substantial doubt about the company's ability to continue as a going concern, as highlighted by the independent auditor.
• Ongoing legal disputes with Mayne Pharma could result in significant damages, indemnification obligations, or offsets against future royalty payments, materially affecting liquidity.
• The company is dependent on third parties (licensees) for product sales and manufacturing, introducing risks related to their performance and compliance.
• Patent infringement lawsuits by Teva Pharmaceuticals and Sun Pharma against IMVEXXY could lead to generic competition and a reduction in royalty rates earlier than expected (LOE).

Risks

• All revenue is derived from royalties, and failure of licensees to maintain or increase sales could adversely affect the business.
• Incurred net losses in the past and may not maintain or increase profitability in the future.
• Substantial doubt exists about the company's ability to continue as a going concern.
• Dependence on third parties for manufacturing and supply of products may cause delays or prevent successful commercialization.
• Commercial success depends on gaining and retaining significant market acceptance among physicians and payers.
• Coverage and reimbursement may not be available for products, making profitable sales difficult for licensees.
• Revenue, results of operations, and financial position could be affected by ongoing disputes with Mayne Pharma.
• Time and costs associated with winding down general and administrative, commercial, and research and development activities may be significant.
• Could be affected by transitions in senior management team, especially given the reliance on a single CEO.
• Subleasing properties could expose the company to liabilities and losses if subtenants default.
• Licensing of intellectual property involves complex legal, business, and scientific issues, and disputes could jeopardize rights.
• Reliance on Mayne Pharma to prosecute, file lawsuits, or take other actions to protect or enforce intellectual property, with no guarantee of success or willingness.
• Inadequate protection of intellectual property could lead to competitors using technologies and eroding competitive advantage.
• Products face significant competition from branded and generic products, which could reduce operating results.
• Success is tied to the distribution channels of licensees; any failure to maintain sales force or effectively implement strategies will impede growth.
• Future success depends on the ability to attract and retain qualified personnel, currently relying on one employee and external consultants.
• Failure to maintain compliance with Nasdaq's continued listing requirements could result in delisting.
• May be treated as a public shell company, leading to negative consequences including potential Nasdaq delisting.
• Principal stockholder (Rubric Capital Management LP) owns a significant percentage (25.5%) of stock, exerting significant control over stockholder approval matters.
• Failure to maintain proper internal controls could impair the ability to produce accurate financial statements or comply with regulations.
• No current intention to pay dividends, limiting returns to stock value appreciation.
• Provisions in charter documents and Nevada law may have anti-takeover effects.
• Business may be affected by unfavorable publicity or lack of consumer acceptance.
• Licensees may initiate product recalls or withdrawals or be subject to regulatory enforcement actions.
• Product liability lawsuits could divert resources, result in substantial liabilities, and reduce commercial potential.
• Failure to maintain optimal inventory levels by licensees could harm reputation and lead to financial losses.
• Business may be impacted by new or changing tax laws or regulations.
• May not be able to maintain effective and efficient information systems or properly safeguard them, leading to cybersecurity risks.
• Failure to comply with foreign data protection laws and regulations could lead to government enforcement actions and significant penalties.
• Employees and business partners may not appropriately secure and protect confidential information.
• Employees may engage in misconduct or other improper activities, including noncompliance with regulatory standards and insider trading.
• Litigation for infringing intellectual property rights of third parties will be costly and time-consuming.
• Inability to protect the confidentiality of certain information could adversely affect product and technology value.
• Unsuccessful exploration of strategic alternatives could materially adversely affect financial condition and results of operations.
• May be subject to claims that former employees wrongfully used or disclosed alleged trade secrets.

Future Outlook

The company's ability to fund operations over the next twelve months is dependent on continued royalty payments, favorable resolution of the Mayne Lawsuits, and minimizing operating expenses. It may need to raise additional capital through equity or debt financing, which could dilute existing stockholders. The company continues to evaluate strategic alternatives, including potential acquisitions, mergers, or other business combinations.

Management Comments

• Management continues to monitor the unresolved and pending net working capital items as changes to estimated amounts owed or amounts due from Mayne Pharma may be material.
• We continue to believe our estimated allowances for payer rebates and wholesale distributor fees are reasonable.
• We believe that corrective actions to address the compliance issues identified in the referenced Forms 483 have been implemented by the CMOs and that the CMOs continue to have the right to manufacture under current regulations.
• We believe our patents and trademarks are valuable and provide us certain benefits in marketing our products. We intend to actively protect our intellectual property.

Industry Context

StockSavvy.ai notes that TherapeuticsMD's pivot to a pharmaceutical royalty model aligns with a broader industry trend where companies monetize intellectual property through licensing to reduce operational overhead and risk associated with direct commercialization. However, this model introduces significant dependence on licensee performance and exposes the company to legal and regulatory risks related to product commercialization by third parties. The ongoing patent challenges for IMVEXXY by generic manufacturers like Teva and Sun Pharma are typical in the pharmaceutical industry, where generic entry significantly impacts branded product revenues. The company's lean operational structure, with only one full-time employee, is an extreme example of this royalty-focused strategy, contrasting sharply with traditional pharmaceutical companies that maintain extensive R&D, manufacturing, and sales infrastructure.

Comparison to Industry Standards

• The company's royalty rates of 8.0% on the first $80.0 million in annual net sales and 7.5% above that, with a decrease to 2.0% upon generic launch, are within the typical range for pharmaceutical licensing agreements, which can vary widely based on product stage, market potential, and intellectual property strength.
• The minimum annual royalties of $3.0 million per year for 12 years, adjusted for inflation, provide a baseline revenue stream, which is a common feature in such agreements to ensure a predictable income floor for the licensor.
• The substantial doubt about the company's ability to continue as a going concern, as noted by its auditor, places it significantly below industry standards for financial stability and operational viability, where most established pharmaceutical royalty companies demonstrate robust cash flows and strong balance sheets.

Management Changes

Corporate Governance

Legal Proceedings

• **Teva Pharmaceuticals IMVEXXY Patent Infringement Lawsuit:** Filed in April 2020 against Teva Pharmaceuticals USA, Inc. in the U.S. District Court for the District of New Jersey, alleging infringement of IMVEXXY patents. Teva seeks approval for a generic version of IMVEXXY, claiming patents are invalid or not infringed. The litigation was stayed until November 2024 and is now ongoing, progressing to claim construction. Legal costs of $2.334 million have been capitalized.
• **Sun Pharma IMVEXXY Patent Infringement Lawsuit:** Filed in July 2024 by TherapeuticsMD and Mayne Pharma against Sun Pharma Inc. in the U.S. District Court for the District of New Jersey, alleging infringement of IMVEXXY patents. Sun Pharma seeks approval for a generic version, claiming patents are invalid or not infringed. Litigation is ongoing and has progressed to claim construction.
• **Mayne Lawsuit (TherapeuticsMD vs. Mayne Pharma):** Filed on April 8, 2025, in the U.S. District Court for the District of Delaware, seeking damages for breach of contract, breach of implied covenant of good faith and fair dealing, fraudulent inducement, and unjust enrichment related to net working capital allowances and Mayne Pharma's actions. An amended complaint was filed on June 20, 2025. A magistrate judge recommended granting-in-part and denying-in-part Mayne's motion to dismiss on March 23, 2026, and recommended staying the lawsuit for dispute resolution on net working capital claims.
• **Mayne Countersuit (Mayne Pharma vs. TherapeuticsMD):** Filed on May 30, 2025, in the U.S. District Court for the District of Delaware, seeking damages for breach of contract and fraudulent inducement, and making indemnification demands. A magistrate judge recommended granting TherapeuticsMD's motion to dismiss the fraudulent inducement claim but denying dismissal of other claims on March 23, 2026.

Related Party Transactions

• **Rubric Capital Management LP:** Justin Roberts, a director, is a Partner at Rubric. Rubric and its affiliates beneficially owned approximately 25.5% of common stock as of March 23, 2026.
• **Subscription Agreements with Rubric:** On May 1, 2023, the company entered into a Subscription Agreement with Rubric to sell up to 5,000,000 shares of common stock. In 2023, Rubric purchased 312,525 shares for $1.15 million and an additional 877,192 shares for $2.0 million. No drawdowns occurred in 2024 and 2025.

Stakeholder Impact

• **Shareholders:** Face significant risk of dilution from potential future capital raises. The 'going concern' warning and ongoing legal disputes create substantial uncertainty regarding the company's long-term viability and stock price performance. The concentration of ownership by Rubric Capital Management LP (25.5%) means a single entity can exert significant control over corporate matters.
• **Employees:** The company operates with only one full-time employee (CEO), making it highly dependent on this individual and external consultants. Loss of key personnel or consultants could severely impact operations.
• **Licensees (Mayne Pharma, Knight, Theramex):** Their commercial success directly impacts TherapeuticsMD's royalty revenues. The ongoing legal disputes with Mayne Pharma could strain the relationship and affect the effectiveness of the licensing agreements.
• **Creditors:** The 'going concern' warning indicates increased risk for any potential or existing creditors, as the company's ability to meet its financial obligations is in doubt.
• **Regulatory Authorities:** The company and its licensees remain subject to extensive and costly government regulations, including FDA post-approval requirements and healthcare fraud and abuse laws. Non-compliance could lead to sanctions and impact royalty revenues.

Next Steps

• Resolution of the Mayne Lawsuits, including net working capital claims, through litigation or dispute resolution process.
• Continued defense against patent infringement lawsuits by Teva Pharmaceuticals and Sun Pharma for IMVEXXY.
• Potential pursuit of various equity and debt financing and other alternatives to address capital needs and liquidity requirements.
• Monitoring of Mayne Pharma's sales of licensed products and supply chains related to third-party contract manufacturers.
• Continued evaluation of strategic alternatives, including potential acquisitions, mergers, or other business combinations.

Key Dates

Recommendation

The explicit 'substantial doubt about our ability to continue as a going concern' from the independent auditor is a critical red flag. While royalty revenue increased and net loss decreased, the underlying financial instability, coupled with multiple complex and potentially costly legal disputes (Mayne Pharma, Teva, Sun Pharma) and a highly concentrated, lean operational structure, presents an extremely high-risk profile. The potential for significant liabilities from these lawsuits, combined with the need for future dilutive capital raises, makes the stock a strong sell for seasoned investors and institutions, as the risk of capital loss far outweighs any speculative upside.

Keywords

Pharmaceutical Royalty Company, SEC Filing, 10-K/A, TherapeuticsMD, TXMD, IMVEXXY, BIJUVA, ANNOVERA, Mayne Pharma, Patent Infringement, Going Concern, Liquidity, Women's Healthcare, Royalty Revenue, Legal Proceedings, Corporate Governance, Nasdaq Listing, Financial Performance